Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)

The summary for the Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional): The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across NHGRIs scientific areas and will incorporate a plan for strategies to facilitate inclusive and diverse perspectives. Applications from New or Early Stage Investigators from diverse backgrounds are encouraged. This R21 FOA will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Federal Grant Title:	Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HG-23-018
Type of Funding:	Grant
CFDA Numbers:	93.172, 93.313, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	July 8th, 2025
Original Application Deadline:	July 8th, 2025
Posted Date:	June 5th, 2023
Creation Date:	June 5th, 2023
Archive Date:	August 13th, 2025
Total Program Funding:
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	June 5th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-018.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required); • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed); • Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed); • Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44); • Near-Term Technology Development for Genome Sequencing - STTR (R41/R42); • Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health: • Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Cli...; • Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Cli...; • Specialized Alcohol Research Centers (P50 Clinical trial Optional); • Comprehensive Alcohol Research Centers (P60 Clinical trial Optional); • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed)